www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Cardiovascular diseases
All latest versions
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Antithrombotic medications
Aprocitentan
Dabigatran
G
Proteïne C
IND
Hemostasis promoting medication
Emicizumab
IND
Eptacog beta (activated)
Etranacogene dezaparvovec
Fidanacogene elaparvovec
Nonacog beta pegol
IND
Peboctocogene camaparvovec
Valoctocogene roxaparvovec
Vonicog alfa
IND
Lipid-lowering medications
Alirocumab
IND
Bempedoic acid
Evinacumab
Other medication for cardiovascular diseases
Angiotensin II
Dapagliflozine
IND
Etripamil
Icosapent ethyl
Macitentan
IND
Macitentan / tadalafil
Mavacamten
Neoatricon (dopamine)
Omecamtiv mecarbil
Rexlemestrocel-L
Rilonacept
Sotagliflozine
IND
Valsartan / sacubitril
IND
Vericiguat
Other non-oncological hematological medications
Bentracimab
Concizumab
Hemofilie A en B zonder inhibitors
IND
Hemofilie A met inhibitors en hemofilie B met inhibitors
Crizanlizumab
Crovalimab
Danicopan
Daprodustat
Eculizumab
BS
Efanesoctocog alfa
Efgartigimod
Exagamglogene autotemcel
Ferumoxytol
Hydroxycarbamide
IND
Iptacopan
Luspatercept
IND
Methoxy polyethylene glycol-epoetin beta
IND
Mitapivat
Mozafancogene autotemcel
Pegcetacoplan
Paroxysmal nocturnal haemoglobinuria (PNH)
Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor
IND
Ravulizumab
Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.
Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH): - bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit. - bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab.
IND
UM171
Vadadustat
Voxelotor
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
About the Horizon Scan
Nederlands
English